Status:

COMPLETED

Memory and Antioxidants in Vascular Impairment Trial

Lead Sponsor:

Sunnybrook Health Sciences Centre

Conditions:

Vascular Cognitive Impairment no Dementia

Eligibility:

All Genders

55-85 years

Phase:

PHASE2

Brief Summary

This is a 24-week randomized, double-blind, placebo-controlled parallel group design study involving Vascular cognitive impairment-no dementia (VCIND) patients to evaluate the efficacy and safety of o...

Eligibility Criteria

Inclusion

  • Males or females aged 55-80 years.
  • MoCA score of less than 28.
  • Modest deficits (1 SD below population norm) in executive function, memory, processing speed, or working memory based on the 60-minute battery recommended by the NINDS-CSN.
  • Speaks and understands English.
  • Enrollment in the Cardiac Rehabilitation program at the University Health Network Toronto Rehabilitation Institute.

Exclusion

  • A history of stroke
  • A history of epilepsy
  • Uncontrolled asthma (requiring hospitalization or ER visit in the last 3 months by patient report)
  • Uncontrolled diabetes (clinical determination)
  • Severe hypo/hypertension (clinical determination)
  • Uncontrolled hypercholesterolemia (clinical determination)
  • Presence of significant medical illnesses (Severely disturbed liver function, Severely disturbed kidney function, Severely disturbed lung function, HIV, HBV and/or HCV infection, Malignant tumors)
  • A current neurological condition (Parkinson's disease, Multiple sclerosis, Significant traumatic brain injury)
  • Major psychiatric condition (Current major depressive disorder, Schizophrenia, Bipolar disorder, Substance use disorder (alcohol abuse, heavy smoking (20 cigarettes or more/day))
  • Contraindication to MRI or MRS (e.g. metal in body, pacemaker).
  • Contraindication to NAC (documented allergy) or allergy to lactose.
  • Daily Nitroglycerin use.
  • Bleeding disorders (e.g. hemophilia, Thrombotic Thrombocytopenic Purpura) and/or elective surgery within 30 days.
  • Volunteers who currently participate in another pharmacological study.

Key Trial Info

Start Date :

April 30 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 27 2023

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT03306979

Start Date

April 30 2018

End Date

September 27 2023

Last Update

March 26 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Sunnybrook Health Sciences Centre

Toronto, Ontario, Canada, M4N 3M5